Abstract

Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.

Author affiliations

1. Yves Agid: Physiologie and Pathogénie des Maladies Neurodégénératives, INSERM U 289, Hôpital Salpêtrière, 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
2. György Buzsáki: Center for Molecular and Behavioural Neuroscience, Rutgers University, 197 University Avenue, Newark, New Jersey 07102, USA.
3. Emmanuel Canet: IDRS, 11 Rue des Moulineaux, 92150 Suresnes, France.
4. Graham Collingridge: Department of Anatomy, Medical School, University of Bristol, University Walk, Bristol, BS8 1TD, UK.
5. André Delacourte: 75 Rue Gambetta, 59045 Falmes Thumesnil, France.
6. David M. Diamond: Medical Research Division, Veterans Hospital and University of South Florida, Departments of Psychology and Pharmacology, 4202 East Fowler Avenue (PCD 4118G) Tampa, Florida 33620-8200, USA.
7. Ray Dolan: Wellcome Department of Imaging Neuroscience, Institute of Neurology, 12 Queen Square, London, WC1N 3BG, UK.
8. Philippe Fossati: Service de Psychiatrie d'Adultes, Hôpital Pitié Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris, France.
9. Richard Frackowiak: Wellcome Department of Imaging Neuroscience, Institute of Neurology, 12 Queen Square, London, WC1N 3BG, UK.
10. Jay Giedd: Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health (NIMH/NIH), Room 4C110, 10 Center Drive, MSC 1367, Bethesda, Maryland 20892, USA.
11. Jean-Antoine Girault: INSERM U 536, Institut du Fer à Moulin, 17 Rue du Fer à Moulin, 75005 Paris, France.
12. Anthony Grace: University of Pittsburgh, Department of Neuroscience, 458 Crawford Hall, Pittsburgh, Pennsylvania 15260, USA.
13. Therese Jay: INSERM E0117, 2 Ter Rue d'Alésia, 75014 Paris, France.
14. Jeremy J. Lambert: Neurosciences Institute, Division of Pathology and Neuroscience, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK.
15. Jean-Pierre Lepine: Hôpital Fernand Widal, Psychiatrie Adultes (CS), 200 Faubourg St Denis, 75475 Paris Cedex 10, France.
16. Pierre Lestage: IDRS, 11 Rue des Moulineaux, 92150 Suresnes, France.
17. Husseini Manji: Mood and Anxiety Disorders Program, DIRP/NIMH/NIH, Building 15K, Room 102, 15K Northdrive Bethesda, Maryland 20892 2670, USA.
18. Bernard Marchand: IRIS, 6 Place des Pléiades, 92415 Courbevoie, France.
19. Helen Mayberg: Emory University School of Medicine, 101 Woodruff Circle, WMB 4-313, Atlanta, Georgia 30322, USA.
20. Mark J. Millan: IDRS, 11 Rue des Moulineaux, 92150 Suresnes, France.
21. Laurent Perret: IRIS, 6 Place des Pléiades, 92415 Courbevoie, France.
22. Maurizio Popoli: University of Milan, Center of Neuropharmacology-Department of Pharmacological Sciences, Via Balzaretti 9, 20133 Milano, Italy.
23. Alain Prochiantz: Ecole Normale Supérieure, CNRS UMR 8542, 46 Rue d'Ulm, Paris 75005, France.
24. Gal Richter-Levin: Brain and Behaviour Research Center, University of Haifa, Haifa 31905, Israel.
25. Peter Somogyi: MRC Anatomical Neuropharmacology Unit, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3TH, UK.
26. Michael Spedding: IDRS, 11 Rue des Moulineaux, 92150 Suresnes, France.
27. Per Svenningsson: Karolinska Institute, Section of Molecular Neuropharmacology, Nanna Svartz Väg 2-4, 171 77 Stockholm, Sweden.
28. Léon Tremblay: Neurologie et Thérapeutique expérimentale, INSERM U 289, Hôpital Pitié Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris, France.
29. Stéphane Vandenabeele: IDRS, 11 Rue des Moulineaux, 92150 Suresnes, France.
30. Daniel Weinberger: Clinical Brain Disorder Branch, NIH/NIMH 900 Rockville Pike, Building 10, Room 4S237B, Bethesda, Maryland 20892, USA.

Correspondence to: Michael Spedding²⁶ Email: michael.spedding@fr.netgrs.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.